On September 12th, 2018 Maricann shipped the first batch of Mariplant CBD capsules to be sold in Munich and the Greater Munich region followed by a shipment on September 14th, 2018 to the Greater Cologne region.
The delivery of this initial order of Mariplant CBD capsules marks the next step in Maricann’s European strategy to supply quality, differentiated products to European markets. German consumers will now be able to purchase the product online (www.mariplant.de) and at their local pharmacy. The Company plans a larger scale roll out of pharmacy distribution across Germany in the coming weeks and months.
The first shipment of capsules included Maricann’s differentiated CBD gel capsules that include the patent protected VESIsorb®. VESIsorb® is Maricann’s world class drug delivery technology that allows the Company to produce a superior product to the fast-growing European CBD market at a competitive price.
As stated in previous communications, VESIsorb® has been used in a number of fat soluble pharmaceuticals and nutraceuticals for over 30 years to increase absorption and efficacy. In November of 2017, Maricann purchased the rights for use of the VESIsorb® technology in all cannabis products (see press release dated August 22, 2017). This will allow the Company to develop a full suite of products ranging from finished dose pharmaceuticals to functional beverages while maintaining quality, predictable dosing, and consistent efficacy.
“Our vision is: To enhance lives through cannabis, and with our products now accessible in the German market, we’re achieving our vision. This is no longer a concept, but reality,” stated Ben Ward, CEO of Maricann.
The Company expects additional orders from other pharmacies throughout the growing German market in the coming weeks as more product becomes available. Furthermore, sales from the Company’s online shop www.Mariplant.de continue to demonstrate the German demand for Maricann’s products.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) buildout and will continue to pursue new opportunities in Europe.
Forward Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include references to the Company’s plan for a larger sale roll out of pharmacy distribution across Germany, the development of a full suite of products and expectations for additional orders. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
For more information about Maricann, please visit our website at www.maricann.com
Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
European Headquarters (Germany)
Thierschstrasse 3, 80538 Munchen, Deutschland